- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05380414
Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
July 11, 2023 updated by: Centre Leon Berard
A Single-center, Prospective Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
The proposal is to implement a molecular screening program for advanced/metastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patients for rationale personalized medicine with targeted agents and/or combination involving a chemotherapy backbone.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
750
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Philippe CASSIER, MD, PhD
- Phone Number: 0426556833
- Email: philippe.cassier@lyon.unicancer.fr
Study Locations
-
-
-
Lyon, France, 69373
- Recruiting
- Centre LEON BERARD
-
Contact:
- Philippe CASSIER, MD, PhD
- Phone Number: 0426556835
- Email: philippe.cassier@lyon.unicancer.fr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female patient > 18 years
- metastatic or advanced PDAC
- Patient pretreated with no more than one prior systemic chemotherapy for metastatic/advanced disease (radiotherapy is not counted as a line of therapy).
- Availability of an archival representative FFPE tumor sample from primary tumor (surgery or diagnostic biopsy) and/or from metastatic lesion if metastatic disease at initial diagnosis with associated pathology report from an archival tumor block.
- Life expectancy > 3 months
- PS score 0 or 1.
Exclusion Criteria:
- Curative therapy available
- Any condition contraindicated with blood sampling procedures required by the protocol.
- Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer.
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metastatic/advanced PDAC Patients
Tumor samples
|
Molecular screening
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial.
Time Frame: At the end of study (5 years)
|
At the end of study (5 years)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-Free Survival (PFS)
Time Frame: Up to 12 months
|
Up to 12 months
|
Time from ICF signature to day 1 of next line of therapy
Time Frame: At day 1
|
At day 1
|
Number of patients initiating a targeted therapy according to this molecular screening program with type of therapy initiated
Time Frame: At the end of study (5 years)
|
At the end of study (5 years)
|
Best overall response (BoR)
Time Frame: Up to 12 months
|
Up to 12 months
|
Overall survival (OS)
Time Frame: Up to 12 months
|
Up to 12 months
|
Duration of response (DoR)
Time Frame: Up to 12 months
|
Up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Philippe CASSIER, MD, PhD, Centre LEON BERARD
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2022
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2027
Study Registration Dates
First Submitted
May 10, 2022
First Submitted That Met QC Criteria
May 16, 2022
First Posted (Actual)
May 18, 2022
Study Record Updates
Last Update Posted (Actual)
July 12, 2023
Last Update Submitted That Met QC Criteria
July 11, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ET21-399 GENOPANC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Pancreatic Cancer
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)CompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Dana-Farber Cancer InstitutePatient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in OncologyCompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal AdenocarcinomaUnited States
-
University Hospital HeidelbergGerman Cancer Research CenterCompletedColorectal Cancer Metastatic | Pancreatic Cancer MetastaticGermany
-
HonorHealth Research InstituteUniversity of Arizona; Agenus Inc.; Translational Genomics Research InstituteNot yet recruitingPancreatic Cancer Metastatic | Pancreatic Adenocarcinoma MetastaticUnited States
-
Pancreatic Cancer Action NetworkActive, not recruitingMetastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic CancerUnited States
-
Joachim Aerts, MD PhDCompletedMetastatic Pancreatic CancerNetherlands
-
Georgetown UniversityNational Cancer Institute (NCI); Mayo Clinic; Emory University; Indiana University and other collaboratorsTerminatedMetastatic Colorectal Cancer | Pancreatic Adenocarcinoma | Colorectal Adenocarcinoma | Metastatic Pancreatic CancerUnited States
Clinical Trials on Tumor samples (archival FFPE) and blood samples
-
Centre Leon BerardRecruiting
-
UNC Lineberger Comprehensive Cancer CenterAmerican Society of Clinical OncologyRecruitingCarcinoma, Squamous Cell | Head and Neck NeoplasmUnited States
-
Institut Paoli-CalmettesInstitut National de la Santé Et de la Recherche Médicale, France; Beckman...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Institut Claudius RegaudRecruitingCervical Cancer | Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Anal Cancer | Cervical Intraepithelial Neoplasia 3 | Glioblastoma Multiforme of Brain StemFrance
-
Centre Francois BaclesseRecruiting
-
University Hospital, Basel, SwitzerlandRecruiting
-
Centre Leon BerardHoffmann-La RocheActive, not recruitingSoft Tissue Sarcoma | Metastatic Cancer | Advanced CancerFrance
-
Centre Francois BaclesseRecruiting
-
University Hospital, ToulouseRecruitingBladder Cancer | Urothelial CarcinomaFrance